The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.

Highlights: [•] EGFRvIII downregulates miR-520-3p which upregulates E2F-1 and ensuing TS in HCC. [•] 5-FU plus mAb CH12 has an additive antitumor effect on EGFRvIII-positive HCC. [•] CH12-elicited TS suppression contributes to increased sensitivity to 5-FU in HCC. [•] CH12 is a promising agent to circumvent EGFRvIII-mediated 5-FU-resistance in HCC. [Copyright &y& Elsevier]